Drug intelligence / Profile preview

11-valent recombinant human papilloma virus vaccine

Development stage: Phase 3
Lead developer: National Vaccine and Serum Institute
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The 11-valent recombinant human papilloma virus vaccine is a pharmaceutical vaccine designed to prevent Human Papillomavirus (HPV) infection. It is composed of HPV antigen proteins and is produced by ChinaVaccineSerum. The vaccine is currently undergoing clinical evaluation to assess its safety and ability to induce an immune response in women.

Other names: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

Targets

HPV L1 (Human papillomavirus L1 capsid protein)

Beyond the preview

Go deeper on 11-valent recombinant human papilloma virus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11-valent recombinant human papilloma virus vaccine.

Explore the full profile